Alert message
Alert message

The Latest in Multiple Myeloma News and Treatment

Email this program

Get Link

When it comes to the serious blood related cancer, multiple myeloma, the good news is definitely that knowledge is power. Treatments are changing, clinical research is encouraging and people are living with the disease. Almost 20,000 people are diagnosed each year in the U.S. and 100,000 people are in treatment at any one time. Fortunately, the range of treatments is expanding and even the newest drugs are being combined in powerful ways. It's gotten so printed information becomes out of date pretty fast. That's why we are happy to announce a series of seven live, 1 hour Special Edition online only webcasts where you can hear the latest myeloma news from leading experts and inspiring, experienced patients and ask them questions.

Here is our schedule of webcasts. Check back often as we will continually update this information with names of guests and other details. Also, be sure to send in questions as you have them and sign up for our Special Edition newsletter and alerts.

Whenever major clinical studies are first presented pertaining to the latest and most effective treatment for myeloma, such as those presented at the American Hematology Society meeting in December, it generates questions. Our job, in our continuing series of myeloma webcasts, is to answer them.

You may be wondering: "How do these latest studies apply to me and having better health? How can these results help guide me in discussions with my doctor?" In our next webcast, you will get the opportunity to hear answers from a leading myeloma specialist, Dr. Sagar Lonial. He'll explain the latest developments in myeloma treatments during our one-hour, Special Edition program, which will air LIVE-online only at www.patientpower.info -- this Friday, March 7, beginning at 2 p.m. Eastern, 11 a.m. Pacific.

Remember, our discussions are meant to help give you expert perspective and it would be unwise and unfair to you to try to practice medicine over the Web. Please recognize that for specific medical advice you should consult with your own doctor.

With that caveat, you are welcome to submit a question below in advance or during the live program. And please, tell others about our live programs and the replays and transcripts that are posted soon after the live broadcasts. There is nothing like this anywhere else. 

As always, we welcome your comments and suggestions.

Sagar Lonial

Sagar Lonial, M.D. is an Associate Professor at the Winship Cancer Institute of Emory University, and is also Director of Translational Research, B-cell malignancy program. He is on staff and works both on the bone marrow transplant service as well as in the B-cell malignancy clinic. Dr. Lonial completed his Hematology-Oncology training at Emory University, and prior to that received his Internal Medicine residency at the Baylor College of Medicine in Houston, Texas. There he spent an additional year as a Chief Medical Resident at the Ben Taub General Hospital as well as the Texas Heart® Institute and St. Luke's Episcopal Hospital. Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in previous years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Dr. Lonial's laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, and his lab has recently received funding from the MMRF. Dr. Lonial has received the Lymphoma Research Foundation's Clinical Investigator Award as well as support from the V-Foundation and the American Cancer Society. He is an ad hoc reviewer for Blood, Cancer Research, and other journals, and has authored or coauthored over 30 papers and abstracts.

Advertisement
Advertisement

Page last updated on August 3, 2010